9. Other matters to be factored into investment decisions
- This contract concerns entering into a new trust contract for acquisition of treasury stock.
- The 121,151 shares of "Acquisition within profits available for dividends (shrs.) - Common stock" of "6. Treasury stock holdings before contract" above are the number of shares acquired by August 11, 2022, the date immediately before "7. Date of board resolution (decision date)," and was prepared based on the date of execution of share purchase and sales.
- The 24 shares of "Acquisition for other reasons (shrs.) - Common stock" of "6. Treasury stock holdings before contract" above are the treasury stocks received from the Korea Securities Depository on December 29, 2020, as a result of a par value merger in 1984.
【Limit to Acquiring Treasury Stocks】
Category
Amount (KRW)
1. Limit to "profits available for dividends" in the Commercial Act as of the immediately preceding business year end
ⓐ. Net assets
362,176,922,877
ⓑ. Amount of capital
12,524,652,500
ⓒ. Total amount of capital reserve and earned surplus reserves accumulated up to preceding business year
144,913,646,728
ⓓ. Unrealized gain as prescribed by Presidential Decree
692,419,309
Sub total (ⓐ-ⓑ-ⓒ-ⓓ)
204,046,204,340
2. Acquired amount of treasury stock after previous fiscal year end
3,686,738,800
3. Amount of 'dividends' and related 'earned profit reserve' decided at annual general meeting of shareholders after previous fiscal year end
-
4. Amount of 'interim/quarterly dividends' and related 'earned profit reserves' decided by board of directors after previous fiscal year end
-
5. Amount of trust contract
10,000,000,000
6. Acquisition cost of treasury stock sold after previous fiscal year end (moving average method)
-
Limit to acquisition of treasury stock (1-2-3-4-5+6)
190,359,465,540
【Holding Amount of Treasury Stock before Decision to Enter into Trust Contract】
(in shrs.)
Methods of acquisition
Type of stocks
Beginning balance
Change
Closing balance
Remarks
Acquisition (+)
Disposal (-)
Share retirement (-)
Amount of stocks acquired within profits available for dividends
Direct acquisition
Direct acquisition in exchange
Common stock
-
-
-
-
-
-
Different classes of stocks
-
-
-
-
-
-
Direct acquisition in OTC
Common stock
-
-
-
-
-
-
Different classes of stocks
-
-
-
-
-
-
Tender offer
Common stock
-
-
-
-
-
-
Different classes of stocks
-
-
-
-
-
-
Sub total (a)
Common stock
-
-
-
-
-
-
Different classes of stocks
-
-
-
-
-
-
Acquisition by trust contract
Number of stocks indirectly held through trust contracts
Common stock
11,679
58,163
-
-
69,842
-
Different classes of stocks
-
-
-
-
-
-
Number of stocks directly held
Common stock
51,309
-
-
-
51,309
-
Different classes of stocks
-
-
-
-
-
-
Sub total (b)
Common stock
62,988
58,163
-
-
121,151
-
Different classes of stocks
-
-
-
-
-
-
Amount of stocks acquired for other reasons (c)
Common stock
24
-
-
-
24
-
Different classes of stocks
-
-
-
-
-
-
Total (a+b+c)
Common stock
63,012
58,163
-
-
121,175
-
Different classes of stocks
-
-
-
-
-
-
Attachments
Original Link
Original Document
Permalink
Disclaimer
Chongkundang Holdings Corp. published this content on 17 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 August 2022 05:13:05 UTC.
CHONGKUNDANG HOLDINGS CORP., formerly Chong Kun Dang Pharmaceutical Corp., is a Korea-based company engaged in the investment business. Through its subsidiary, the Company provides pharmaceuticals, including remedies for high blood pressure and high cholesterol, immunosuppressive drugs, antitumor agents, antibiotics, remedies for erectile dysfunction and remedies for obesity. It also produces antitumor agents, antibiotics, digestives, circulation agents, respiratory agents, remedies for endocrine diseases, remedies for skin diseases, functional cosmetics and others, as well as pharmaceutical ingredients. On November 2, 2013, the Company divested its pharmaceutical business into a newly established wholly owned subsidiary. After the divestiture, the Company engages in the investment and holding business.